News |

AskGene Pharma Dosed First Patient in Phase 3, Pivotal Trial of ASKB589 in First-Line Advanced Gastric and Gastroesophageal Junction Cancers

Camarillo, California, January 26, 2024 – AskGene Pharma Inc. announces dosing of the first patient at a participating site in China for the Phase III Read More
News |

AskGene Presents Interim Results of ASKB589 (anti-CLDN18.2 antibody) in Combination with CAPOX and PD-1 Inhibitor at ASCO-GI 2024

Camarillo, California, January 18, 2024 - AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Read More
News |

AskGene Pharma Received Clearance to Commence Pivotal Phase III Clinical Trial in China for ASKB589

Camarillo, California, October 16, 2023 - AskGene Pharma Inc. announces that the Center for Drug Evaluation (CDE) of the Chinese National Medicinal Product Administration (NMPA) Read More
News |

AskGene Achieves “First in Human” Milestone for ASKG915, A First-in-Class Anti-PD-1/IL-15 Prodrug for the Treatment of Solid Tumors

Camarillo, California, August 21, 2023 - AskGene Pharma Inc. is pleased to announce that the first patient has been dosed at Columbia University Irving Medical Read More
News |

AskGene IGCC 2023 Oral Presentation: Latest Results of ASKB589 Phase I/II Trial

Camarillo, California, June 16, 2023 - AskGene Pharma Inc. today gave an oral presentation at the 15th International Gastric Cancer Congress (IGCC 2023) in Yokohama, Read More
News |

AskGene Will Give an Oral Presentation on the Latest Clinical Results for ASKB589 at IGGC 2023

Camarillo, California, June 2, 2023 - AskGene Pharma Inc. is pleased to announce its participation in the prestigious 15th International Gastric Cancer Congress (IGCC 2023), Read More
News |

AskGene Presents Encouraging Clinical Results on ASKB589 at ASCO-GI 2023

Camarillo, California, January 24, 2023 - AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Read More
News |

AskGene Announces Completion of First Human Dosing of ASKG315, The First IL-15 Prodrug in Clinical Development

Camarillo, California, December 30th, 2022 - AskGene Pharma Inc. is pleased to announce that the first patient completed their first dose (Cycle 1, Day 1) Read More
News |

AskGene Announces Clearance of IND Application by US FDA for ASKG915, A First-in-Class Anti-PD-1-IL-15 Prodrug Fusion Molecule for the Treatment of Patients with Solid Tumors

Camarillo, California, December 30th, 2022 - AskGene Pharma Inc. is pleased to announce that the United States Food and Drug Administration (FDA) has cleared its Read More